@Article{jml474,
AUTHOR = {Salama, Hemat Abd El Salam Ahmed and El-Shayeb, Mohamed Abd El-Rahman Hassan and Hassan, Ahmed Nour El-Din and Amin, Ghada Essam El-Din and Allam, Mohamed Farouk and Ahmed, Eman El- Sayed},
TITLE = {Ivermectin for Treatment of COVID-19?},
JOURNAL = {Journal of Mathematics Letters},
VOLUME = {1},
YEAR = {2022},
NUMBER = {1},
PAGES = {30-31},
URL = {https://www.scipublications.com/journal/index.php/WJMM/article/view/474},
ISSN = {ISSN Pending},
DOI = {10.31586/wjmm.2022.474},
ABSTRACT = {Many attempts have been made to repurpose existing and approved drugs for the treatment of COVID-19 infection. This involves anti-malarial drugs such as hydroxychloroquine and chloroquine, which have been shown to be less successful than initially believed, with a substantial risk of often fatal complications and interactions. This also involves Remdesivir, which has been shown to decrease recovery time significantly in hospitalized patients. However, for patients who are not yet hospitalized, there is no currently accepted treatment. Treating patients before they need to be admitted or even prophylactically could greatly decrease the load on hospitals, protect healthcare workers and reduce the spread of COVID-19. An in-vitro study indicated that Ivermectin was dynamic against COVID-19-infected cell. Ivermectin has antimicrobial, antiviral, and anticancer, immunomodulatory properties. This drug could reduce the viral load in COVID-9 infected patients, with potential effect on disease progression and spread. Therefore, Ivermectin may be a therapeutic choice for treatment of COVID-19, however, there is still a lack of evidence-based studies to support ivermectin treatment of patients with COVID-19.},
}

%0 Journal Article
%A Salama, Hemat Abd El Salam Ahmed
%A El-Shayeb, Mohamed Abd El-Rahman Hassan
%A Hassan, Ahmed Nour El-Din
%A Amin, Ghada Essam El-Din
%A Allam, Mohamed Farouk
%A Ahmed, Eman El- Sayed
%D 2022
%J Journal of Mathematics Letters

%@ ISSN Pending
%V 1
%N 1
%P 30-31

%T Ivermectin for Treatment of COVID-19?
%M doi:10.31586/wjmm.2022.474
%U https://www.scipublications.com/journal/index.php/WJMM/article/view/474

TY  - JOUR
AU  - Salama, Hemat Abd El Salam Ahmed
AU  - El-Shayeb, Mohamed Abd El-Rahman Hassan
AU  - Hassan, Ahmed Nour El-Din
AU  - Amin, Ghada Essam El-Din
AU  - Allam, Mohamed Farouk
AU  - Ahmed, Eman El- Sayed
TI  - Ivermectin for Treatment of COVID-19?
T2  - Journal of Mathematics Letters
PY  - 2022
VL  - 1
IS  - 1
SN  - ISSN Pending
SP  - 30
EP  - 31
UR  - https://www.scipublications.com/journal/index.php/WJMM/article/view/474
AB  - Many attempts have been made to repurpose existing and approved drugs for the treatment of COVID-19 infection. This involves anti-malarial drugs such as hydroxychloroquine and chloroquine, which have been shown to be less successful than initially believed, with a substantial risk of often fatal complications and interactions. This also involves Remdesivir, which has been shown to decrease recovery time significantly in hospitalized patients. However, for patients who are not yet hospitalized, there is no currently accepted treatment. Treating patients before they need to be admitted or even prophylactically could greatly decrease the load on hospitals, protect healthcare workers and reduce the spread of COVID-19. An in-vitro study indicated that Ivermectin was dynamic against COVID-19-infected cell. Ivermectin has antimicrobial, antiviral, and anticancer, immunomodulatory properties. This drug could reduce the viral load in COVID-9 infected patients, with potential effect on disease progression and spread. Therefore, Ivermectin may be a therapeutic choice for treatment of COVID-19, however, there is still a lack of evidence-based studies to support ivermectin treatment of patients with COVID-19.
DO  - Ivermectin for Treatment of COVID-19?
TI  - 10.31586/wjmm.2022.474
ER  -